Legend Biotech
LEGN
139 hedge funds and large institutions have $2.33B invested in Legend Biotech in 2021 Q4 according to their latest regulatory filings, with 66 funds opening new positions, 44 increasing their positions, 23 reducing their positions, and 14 closing their positions.
371% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 14
91% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 23
58% more funds holding
Funds holding: 88 → 139 (+51)
18% more capital invested
Capital invested by funds: $1.97B → $2.33B (+$357M)
2.95% more ownership
Funds ownership: 13.48% → 16.43% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
53% less call options, than puts
Call options by funds: $2.89M | Put options by funds: $6.1M
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$85.4M |
| 2 |
BlackRock
New York
|
+$79.6M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$40.6M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$38M |
| 5 |
State Street
Boston,
Massachusetts
|
+$27.5M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IF
151
Ironwood Financial
Tucson,
Arizona
| – | -$2K | -40 | Closed |
|
152
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$507 | +10 | New |
|
LEGN Hedge Fund Activity: Q4 2021 in Review
139 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q4 2021, worth a combined $2.33B — up 18% from $1.97B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new LEGN positions and 14 closed out — a net gain of 52 holders — while 44 added to existing stakes and 23 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $85.4M. The largest seller was Matthews International Capital Management, cutting an estimated $17.8M.
- 139 institutional investors held Legend Biotech (LEGN) as of Q4 2021, up from 88 in Q3 2021.
- Funds reported $2.33B of Legend Biotech stock for Q4 2021, up 18% quarter-over-quarter.
- 66 funds opened new Legend Biotech positions in Q4 2021 and 14 closed out, a net change of +52 holders.
- The largest Legend Biotech buyer in Q4 2021 was Wellington Management Group, an estimated $85.4M added.
- The largest Legend Biotech seller in Q4 2021 was Matthews International Capital Management, an estimated $17.8M sold.
Based on aggregated 13F filings for Q4 2021.